Gakis Georgios, Ngamsri Theofanis, Rausch Steffen, Mischinger Johannes, Todenhöfer Tilman, Schwentner Christian, Schmid Manuel Alexander, Hassan Fahmy Al-Sayed, Renninger Markus, Stenzl Arnulf
Department of Urology, Eberhard-Karls University, Hoppe-Seyler Strasse 3, 72076, Tuebingen, Germany.
World J Urol. 2015 Oct;33(10):1429-37. doi: 10.1007/s00345-015-1485-8. Epub 2015 Jan 17.
To investigate whether photodynamic diagnosis (PDD)-guided bladder tumour resection (TUR-BT) is of prognostic value in patients undergoing subsequent radical cystectomy (RC) for bladder cancer (BC).
In 224 consecutive patients who underwent RC and bilateral pelvic lymphadenectomy for BC between 2002 and 2010 (median follow-up 29 months [IQR 8-59]), we retrospectively investigated whether patients had previously undergone PDD-guided (hexaminolevulinate [HAL] vs. 5-aminolevulinate [ALA]) versus white light (WL)-TUR-BT. Kaplan-Meier analysis was used to estimate recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) using log-rank and Cox regression model for uni- and multivariable analysis.
Of the 224 patients, 66 (29.5 %) underwent HAL-, 23 (10.3 %) ALA- and 135 (60.2 %) WL-TUR-BT before RC. The 3-year RFS/CSS/OS was 77.8/83.9/74.0 % for HAL-, 53.6/74.5/60.9 % for ALA- and 52.4/59.7/56.5 % for WL-TUR-BT (p = 0.002/0.023/0.037 for HAL vs. WL/ALA). PDD-TUR-BT was associated with a higher number of TUR-BTs before RC (p < 0.001) and re-resections (p = 0.015), a longer time between the first TUR-BT and RC (p = 0.044) and a lower rate of post-operative systemic chemotherapy (p = 0.001). In multivariable analysis, performance of HAL-TUR-BT, pathologic tumour and nodal stage as well as soft tissue surgical margin status were independent predictors for RFS, CSS and OS.
This series indicates for the first time that HAL-guided TUR-BT is an independent predictor for improved survival after RC.
探讨光动力诊断(PDD)引导下的膀胱肿瘤切除术(TUR - BT)对于后续接受膀胱癌(BC)根治性膀胱切除术(RC)患者的预后价值。
在2002年至2010年间连续224例接受RC及双侧盆腔淋巴结清扫术治疗BC的患者(中位随访时间29个月[四分位间距8 - 59个月])中,我们回顾性研究了患者此前是否接受过PDD引导(六氨基乙酰丙酸[HAL]与5 - 氨基乙酰丙酸[ALA])的TUR - BT或白光(WL)引导的TUR - BT。采用Kaplan - Meier分析评估无复发生存期(RFS)、癌症特异性生存期(CSS)和总生存期(OS),并使用对数秩检验和Cox回归模型进行单变量和多变量分析。
224例患者中,66例(29.5%)在RC前接受了HAL引导的TUR - BT,23例(10.3%)接受了ALA引导的TUR - BT,135例(60.2%)接受了WL引导的TUR - BT。HAL引导的TUR - BT、ALA引导的TUR - BT和WL引导的TUR - BT的3年RFS/CSS/OS分别为77.8/83.9/74.0%、53.6/74.5/60.9%和52.4/59.7/56.5%(HAL与WL/ALA相比,p = 0.002/0.023/0.037)。PDD引导的TUR - BT与RC前更多的TUR - BT次数(p < 0.001)、再次切除术(p = 0.015)、首次TUR - BT与RC之间更长的时间间隔(p = 0.044)以及更低的术后全身化疗率(p = 0.001)相关。在多变量分析中,HAL引导的TUR - BT的实施、病理肿瘤和淋巴结分期以及软组织手术切缘状态是RFS、CSS和OS的独立预测因素。
本系列研究首次表明,HAL引导的TUR - BT是RC后生存改善的独立预测因素。